“ A cell line with knockout of both alleles for the gene responsible for fucose addition (α1,6-fucosyltransferase FUT8) can take advantage of this phenomenon, producing Potelligent mAbs with enhanced ADCC activity.” “ They confirmed that the mechanism behind the enhanced ADCC of a low/no-fucose antibody was its increased affinity to FcγRIIIa (CD16), the major Fc receptor for ADCC in humans. Ltd (now Kyowa Hakko Kirin) demonstrated that an antibody with a reduced fucose content in glycan moieties exhibited much higher antibody dependent cellular cytotoxicity (ADCC) activity compared to a normally fucosylated antibody,” said Fallen. Under the agreement, this host cell line is used to produce the high-ADCC mAbs created by BioWa’s technology.
Its pre-adaptation to suspension culture aids adaptation of GS cell lines back to growth in suspension culture after transfection.”
Karen Fallen, VP of Licensing and Technology at Lonza, told Lonza’s host cell line is “ pre-adapted to growth in chemically defined, animal component-free (CDACF) media and suspension culture. It works in three ways: cancer cell depletion via ADCC, and deprivation of both a key stimulation signal and immune privilege. Lonza said the combined technology is “ designed to improve the potency and efficacy of therapeutic antibodies by enhancing antibody-dependent cellular cytotoxicity (ADCC), one of the major mechanisms of therapeutic antibodies.”ĪrGEN-X will use the tech to develop ARGX-110, a monoclonal antibody in its pipeline which targets CD70 positive tumours. Search for this case: Paul Argen, et al v.Potelligent CHOK1SV cell line is a combination of BioWa’s Potelligent glycosylation technology and Lonza’s GS Gene Expression System, which uses Lonza’s host cell line CHOK1SV. (CJG) Īccess additional case information on PACERĪccess the Case Summary and Docket Report to access additional information about this case on the US Court's PACER system. Notice filed by Appellants Paul Argen and Mr. RECORD available on District Court CM/ECF. (PAC) ĮCF FILER: ENTRY OF APPEARANCE from Paul A Clark on behalf of Appellant(s) Paul Argen Surender Malhan. Surender Malhan and Paul Argen advising this court that no transcripts are available. (PAC) ĮCF FILER: Transcript Purchase Order Form (Part 1) filed by Appellants Mr. (PAC) ĮCF FILER: CIVIL INFORMATION STATEMENT on behalf of Appellants Paul Argen and Mr. Surender Malhan to Expedite Briefing Schedule and Decision. (CJG) ĮCF FILER: Motion filed by Appellants Paul Argen and Mr. ORDER (PHIPPS, Circuit Judge) The motion for expedited briefing schedule and consideration is denied. for David Katz requesting the following document(s): Appearance Form on or before. Surender Malhan and Paul Argen requesting the following document(s): Concise Summary on or before.
(RJM) ĮCF FILER: Concise Summary of the Case filed by Appellants Paul Argen and Mr. McGuire on behalf of Appellee(s) David Katz. (CJG) ĮCF FILER: ENTRY OF APPEARANCE from Robert J. Brief on behalf of Appellants Paul Argen and Surender Malhan due on or before. (PAC) ĮCF FILER: ELECTRONIC BRIEF with Volume I of Appendix attached on behalf of Appellants Paul Argen and Mr. (CJG) ĮCF FILER: ELECTRONIC APPENDIX on behalf of Appellants Paul Argen and Mr. A more recent docket listingĪppellee David Katz verbally granted an extension of time to file brief until pursuant to Third Cir. This docket was last retrieved on March 17, 2020.
0 kommentar(er)
